Clinical Trials Browser

Phase NA × Breakthrough Pain × Passive Cutaneous Anaphylaxis × Clear all

NCT05053308 2023-08-07

Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

Phase NA Withdrawn

Cancer Pain, Breakthrough Pain